AUDIO – NO PENALTIES –
Oct. 23, 2024 – Eisai told everyone that they would be given a genetic test. But the results, the company added, would remain secret.
An autopsy determined that the drug’s side effects had contributed to her death. Her final hours were spent thrashing so violently that nurses had to tie her down. Another high-risk trial volunteer died, and more than 100 others suffered brain bleeding or swelling. “The people who are in charge of the clinical trial have not come to grips with the severity of the toxicity” of Leqembi, said Dr. Rudolph J. Castellani, a pathology professor at Northwestern’s Feinberg School of Medicine in Chicago. Dr. Castellani performed an autopsy on Jean Terrien, the other high-risk volunteer who died during the Leqembi trial.
